Nemetschek's 56% Drop Made This 14.5% Growth Story a Trap-or a Buy Zone

Nemetschek's strong Q2 numbers collided with a much weaker stock

The business still looks high-quality, but sentiment shifted

Nemetschek delivered 14.5% FX-adjusted Q2 revenue growth, an EBITDA margin of 30.1%, and an adjusted EBITDA margin of 31.0% excluding one-offs. Even so, the stock is trading around €58.90 open versus a €138.00 52-week high. That gap is the core tension: the operating story remains strong, but the market is no longer giving it the same premium it did before.

Management also fully confirmed its organic outlook for 2026 and said the broader 2026 outlook was expanded following the HCSS acquisition. At the same time, subscription and SaaS revenue at 80% of group revenues shows the business mix is still moving in the right direction.

The caution is not baseless. Nemetschek said its shares fell 8.93% as investors weighed segment weakness, acquisition dilution and a cautious outlook for some parts of the business. So the real question is not whether the quarter was good. It is whether this was a strong quarter inside a messier setup, or a turning point that the market is still refusing to fully trust.

The issue is not weak growth, but uneven growth across the portfolio

Subscription and recurring revenue remain strong

The clearest positives are easy to spot: subscription and SaaS revenue grew 29.6% in Q2, recurring revenue reached 95% of group revenue, and subscription and SaaS revenues reached a record 80% of group revenues. Those are still exactly the kinds of numbers that support a premium software valuation.

Design margin pressure is why the market hesitated

The problem is that the strength is not evenly spread. Design segment EBITDA margin contracted to 23.9%, which matters because it raises questions about how durable and broad-based the profit quality really is right now.

That does not invalidate the quarter. But it does mean investors are no longer treating Nemetschek as one clean, uniformly improving platform. They are asking how much of the growth is durable, where the margin pressure is coming from, and how quickly the weaker parts of the portfolio stabilize.

HCSS expands the outlook, but it also adds near-term dilution

The HCSS acquisition helps explain both sides of the market's reaction. Nemetschek said the deal will cause about 150 basis points of EBITDA margin dilution in 2026, even as the broader 2026 outlook was expanded relative to the pre-acquisition organic view.

That creates a familiar split in interpretation: operationally, the acquisition widens the opportunity; financially, it can look dilutive before it looks accretive. Investors therefore need a clearer breakdown in coming updates-how much of next year's growth is organic versus acquired, and how quickly acquired revenue starts contributing more cleanly to margins.

What management needs to prove next

At roughly 29.00 P/E, Nemetschek is not obviously cheap. That makes the next few updates more important than the headline growth number alone:

• Show that subscription and SaaS revenue grew 29.6% reflects sustained adoption rather than only migration mechanics.
• Show that the Design segment EBITDA margin contracted to 23.9% is a transition issue that is stabilizing rather than a broader quality problem.
• Show that about 150 basis points of EBITDA margin dilution in 2026 from HCSS is temporary rather than a new lower-margin base.

If those pieces improve, the selloff may start to look like a mix problem rather than a model problem.

The buy case now depends on proof, not just a strong quarter

At a €58.90 open, Nemetschek is still above its €50.80 52-week low and well below its €138.00 52-week high. Against that backdrop, the €84.45 average 12-month price target implies upside only if the next few updates convince investors the company is growing more durably than the market now assumes.

What would support a rerating

First, management has to hold the guidance it already restated. Nemetschek fully confirmed its organic outlook for 2026, and the broader outlook was expanded following the HCSS acquisition.

Second, the market needs Build to look less like a one-quarter standout and more like a durable second growth leg. The recent updates highlighted excellent performance in the Build segment and strong demand in the Build segment. If that momentum holds, it would help offset skepticism in other parts of the portfolio.

Third, AI adoption needs to stay visible. Management said Bluebeam Max, the company's AI-driven product suite, is seeing early adoption above expectations. If that continues, investors get a clearer line from recurring revenue to premium product demand.

If those checkpoints keep improving, the path toward the €84.45 average target becomes easier to defend. If they do not, the stock may still be working through a portfolio mix the market is no longer willing to overlook.